ERBB2 and non-small cell lung carcinoma: In addition, HER2 amplification has been identified as an acquired resistance mechanism in EGFR-mutant NSCLC cancers treated with EGFR inhibitors, occurring in approximately 15% of patients resistant to EGFR TKIs.